Maintenance hemodialysis
Conditions
Interventions
Enoxaparin Anticoagulation Control Group:Anticoagulation therapy with sodium enoxaparin (0.6 mL: 6000 AXa IU/vial, Tianjin Hongri Pharmaceutical Co., Ltd.) was administered at a dose of 2000–5000 IU.
Nafamostat Mesylate Anticoagulation Group:Anticoagulation therapy with nafamostat mesylate was administered, with an initial dose of 30 mg/h (adjusted based on ACT results), provided by Jiangsu Duer P
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age 18–75 years, sex and ethnicity unrestricted. 2.Confirmed chronic kidney disease stage 5 on maintenance hemodialysis (2–3 sessions/week for > 3 months). 3.Concomitant use of anticoagulants (warfarin, NOACs) and/or antiplatelet agents (aspirin, glycoprotein IIb/IIIa inhibitors, etc.); 4.Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1.Known hypersensitivity to anticoagulants such as nafamostat mesylate, heparin, or heparin analogues. 2.Any contraindication to anticoagulation, including coagulation disorders, active bleeding, heparin-induced thrombocytopenia, or documented allergy to anticoagulant agents. 3.Life expectancy < 3 months. 4.Severe cardiac, hepatic, or respiratory failure; active malignancy. 5.Unable or unwilling to provide written informed consent. 6.Enrollment in any other clinical study within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of major bleeding events;; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Anticoagulant efficacy;Dialysis adequacy;The incidence of non-major bleeding events; | — |
Countries
China
Contacts
Public ContactLei Yan
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed